Price (delayed)
$3.37
Market cap
$143.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$65.4M
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled
There are no recent dividends present for RPTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.